| Name | Title | Contact Details |
|---|
Evozyne is a data-driven evolution-based molecular engineering platform for building novel, application-specific proteins with advanced functionality.
Gradalis, Inc. is a fully integrated biotechnology company based in Dallas, Texas that focuses on the development, manufacturing, and commercialization of drugs, vaccines, tools, and diagnostics primarily in the area of cancer. Gradalis has its own GMP manufacturing facility along with highly skilled technical leadership and staff and a strategic partnership with Mary Crowley Cancer Research Centers for clinical development of Gradalis products. The Company has two primary platforms, one centered on personalized autologous vaccines and a second focused on bifunctional short hairpin RNA (shRNA) to enable specific protein knockdown. In addition. Gradalis has numerous partnerships and joint ventures that provide it with access to other cutting edge clinical and pre-clinical stage programs.
BioPorto s flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.
Gemelli Biotech leverages leading biological discoveries related to the microbiome to provide non-invasive precision diagnostics which enable clinicians to definitively detect scientifically validated biomarkers and optimally treat GI diseases including SIBO, IMO, excess hydrogen sulfide and post-infectious IBS.
Clinsys practices this philosophy with its clients. We focus on building long-term relationships and successful partnerships with our pharmaceutical and biotech partners through a total dedication to delivering on commitments, understanding client needs